Capricor Therapeutics (CAPR) News Today

Capricor Therapeutics, Inc. (NASDAQ: CAPR) moved sharply higher amid renewed investor optimism that its lead Duchenne muscular dystrophy treatment, deramiocel, may still have a path to FDA approval. Trading volume was exceptionally heavy, reflecting substantial volatility as investors weighed the regulatory update against legal and financial risks.

• Positive Sentiment: The FDA indicated it is willing to review an amendment to Capricor’s Biologics License Application for deramiocel. The company plans to submit 24-month extension data from the HOPE-3 Phase 3 trial, potentially giving the treatment a regulatory lifeline after an earlier advisory committee rejection. Capricor outlines BLA amendment plan as FDA signals willingness to review
• Positive Sentiment: HOPE-3 results were published in The Lancet, with the trial achieving its primary upper-limb-function endpoint at a statistically significant p-value of 0.029. The data could strengthen Capricor’s case in discussions with regulators. Capricor Therapeutics Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Capricor reported approximately $238 million in cash, cash equivalents and marketable securities as of June 30, providing resources to advance deramiocel and support regulatory activities.
• Neutral Sentiment: A PDUFA decision date of August 22 is being monitored by investors, although the potential impact depends on the FDA’s review of the amended application and the strength of the submitted data.
• Negative Sentiment: Capricor reported a second-quarter loss of $0.70 per share, worse than the $0.59 consensus estimate, underscoring ongoing cash burn and the absence of established commercial revenue. Capricor second-quarter earnings report
• Negative Sentiment: Multiple law firms publicized a securities-fraud class action covering investors who purchased shares from December 17, 2025, through July 26, 2026. The allegations include misleading statements about deramiocel’s FDA approval prospects and deviations from HOPE-3’s prespecified protocol and statistical analysis plan. The lead-plaintiff deadline is September 28, 2026; the claims have not been proven in court. Capricor securities-fraud class action notice